AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus intensive lifestyle intervention
Number of subjects: 699
Study 23704672 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 699
Study 23704912 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 10614
Study 23704912 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant therapy
Number of subjects: 10614
Study 23704912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 10614
Study 23706709 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic markers associated with severe asthma exacerbations (51 markers from 17 genes)
Number of subjects: 199
Study 23706709 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome scan
Number of subjects: 199
Study 23706709 — intervention group
Group type: EXPERIMENTAL
Intervention: Admixture analysis
Number of subjects: 199
Study 23706709 — intervention group
Group type: COMPARATOR
Intervention: Previously reported associations of genetic markers with asthma exacerbations
Number of subjects: 199
Study 23706713 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 40
Study 23706713 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen specific serum IgE (sIgE) testing
Number of subjects: 40
Study 23706713 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) and allergen specific serum IgE (sIgE) testing
Number of subjects: 40
Study 23706985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel at 260 mg/m(2) intravenously every 3 weeks.
Number of subjects: 48
Study 23707147 — intervention group
Group type: COMPARATOR
Intervention: SCA1 mutation carriers
Number of subjects: 264
Study 23707147 — intervention group
Group type: COMPARATOR
Intervention: SCA2 mutation carriers
Number of subjects: 264
Study 23707147 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA1 and SCA2 mutation carriers
Number of subjects: 264
Study 23707169 — intervention group
Group type: COMPARATOR
Intervention: F4/AS01 candidate vaccine
Number of subjects: 38
Study 23707169 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro stimulation with p17, p24, RT antigens
Number of subjects: 38
Study 23709304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 1977
Study 23709304 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR
Number of subjects: 1977
Study 23710653 — intervention group
Group type: EXPERIMENTAL
Intervention: IV anidulafungin
Number of subjects: 54
Study 23710653 — intervention group
Group type: EXPERIMENTAL
Intervention: IV anidulafungin followed by oral voriconazole
Number of subjects: 54
Study 23710698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dilators, topical corticosteroids, and estrogen for vaginal cGVHD.
Number of subjects: 1
Study 23710698 — intervention group
Group type: EXPERIMENTAL
Intervention: Local immunosuppression and dilators for genital GVHD.
Number of subjects: 1
Study 23710697 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 23711443 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical dimethylarginine
Number of subjects: 0
Study 23711443 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 0
Study 23712514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged to home (HD)
Number of subjects: 403
Study 23712514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged to other RFs
Number of subjects: 403
Study 23712514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged to supported housing
Number of subjects: 403
Study 23712514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged to prison
Number of subjects: 403
Study 23712514 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' predictions about HD
Number of subjects: 403
Study 23712514 — intervention group
Group type: EXPERIMENTAL
Intervention: Variables associated with higher HD likelihood
Number of subjects: 403
Study 23712839 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0
Study 23712839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no multivitamin supplementation)
Number of subjects: 0
Study 23714176 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS)
Number of subjects: 1693
Study 23714176 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Geneva score (SGS)
Number of subjects: 1693
Study 23714176 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (readmission rate)
Number of subjects: 1693
Study 23714281 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 29
Study 23715103 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular plasma treatment for hereditary TTP
Number of subjects: 0
Study 23715103 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 23715577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (60 to 120 mg/m(2) once daily)
Number of subjects: 58
Study 23715608 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (positive end-expiratory pressure)
Number of subjects: 12
Study 23715608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate PEEP level
Number of subjects: 12
Study 23715608 — intervention group
Group type: COMPARATOR
Intervention: No PEEP
Number of subjects: 12
Study 23716272 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 21
Study 23716272 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib
Number of subjects: 21
Study 23716272 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib
Number of subjects: 21
Study 23716538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day orally on days 1 - 21 (28-day cycle); melphalan 0.18 mg/kg orally on days 1-4; dexamethasone 40 mg orally on days 1, 8, 15, and 22
Number of subjects: 25
Study 23716538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, melphalan, and dexamethasone
Number of subjects: 25
Study 23716541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2))
Number of subjects: 0
Study 23716765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 70
Study 23716765 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 1 mg
Number of subjects: 70
Study 23718677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 35
Study 23718677 — intervention group
Group type: COMPARATOR
Intervention: Non-anticoagulated individuals (control group)
Number of subjects: 35
Study 23719348 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz, didanosine, and lamivudine (combined therapy)
Number of subjects: 49
Study 23719348 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inhibition score
Number of subjects: 49
Study 23719639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol
Number of subjects: 2734
Study 23719639 — intervention group
Group type: COMPARATOR
Intervention: Budensonide/formoterol
Number of subjects: 2734
Study 23719639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 2734
Study 23719651 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniblocker® inserted into the endotracheal tube and advanced until the blocker balloon just protruded from the endotracheal tube tip
Number of subjects: 56
Study 23719719 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg by intravenous infusion every 3 weeks for up to 16 cycles)
Number of subjects: 52
Study 23719719 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 52
Study 23720019 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with full-dose gemcitabine (1 g/m(2) over 30 minutes on days 1, 8, and 15) and oxaliplatin (85 mg/m(2) on days 1 and 15) with radiation therapy (30 Gray in 2-Gy fractions during cycle 1)
Number of subjects: 68
Study 23720019 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with full-dose gemcitabine, oxaliplatin, and RT
Number of subjects: 68
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy for PAH
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy for PAH
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: No PAH drugs
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year survival rate for PAH-CHD
Number of subjects: 104
Study 23720182 — intervention group
Group type: COMPARATOR
Intervention: 4-year survival rate for idiopathic PAH (IPAH)
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 6-minute walk distance
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (EQ-5 D)
Number of subjects: 104
Study 23720182 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional class distribution
Number of subjects: 104
Study 23720241 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective insomnia defined by polysomnography
Number of subjects: 1042
Study 23720241 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective insomnia symptoms categorized by validated questionnaires
Number of subjects: 1042
Study 23720241 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective DSM-IV insomnia
Number of subjects: 1042
Study 23720241 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective criteria for insomnia
Number of subjects: 1042
Study 23721329 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT-treated patients
Number of subjects: 12
Study 23721329 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab-treated patients
Number of subjects: 12
Study 23721329 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT-treated patients cultured with myelin oligodendrocyte glycoprotein peptides
Number of subjects: 12
Study 23721329 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab-treated patients cultured with myelin oligodendrocyte glycoprotein peptides
Number of subjects: 12
Study 23722308 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocryosurgery (liquid nitrogen, open spray, 2 × 15 s; day 14) during 5 weeks' imiquimod
Number of subjects: 91
Study 23723295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0
Study 23723295 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 0
Study 23724022 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels before SBT
Number of subjects: 88
Study 23724022 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels at the end of SBT
Number of subjects: 88
Study 23724022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung aeration loss during successful weaning trial
Number of subjects: 88
Study 23724022 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels measured at 4 hours after extubation
Number of subjects: 88
Study 23724353 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 370
Study 23724353 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (any dose)
Number of subjects: 370
Study 23724353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 23724881 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performed 1 hour after a standardized breakfast (T1h)
Number of subjects: 16
Study 23724881 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performed 3 hours after a standardized breakfast (T3h)
Number of subjects: 16
Study 23724881 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in postprandial state
Number of subjects: 16
Study 23724914 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study 23725004 — intervention group
Group type: EXPERIMENTAL
Intervention: AllerT (combination of three COPs selected for undetectable IgE binding)
Number of subjects: 0
Study 23725004 — intervention group
Group type: EXPERIMENTAL
Intervention: AllerT4-T5 (second set of COPs with some residual IgE binding)
Number of subjects: 0
Study 23725004 — intervention group
Group type: COMPARATOR
Intervention: rBet v 1 (control)
Number of subjects: 0
Study 23726000 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT (38.5 Gy in 10 fractions twice daily over 5 days)
Number of subjects: 52
Study 23726267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5mg/d plus temsirolimus 25mg/week
Number of subjects: 27
Study 23726267 — intervention group
Group type: COMPARATOR
Intervention: Tivozanib 0.5, 1.0 or 1.5mg/d orally (3 weeks on/1 week off) and temsirolimus 15 or 25 mg/week intravenously
Number of subjects: 27
Study 23726971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m(2) + cisplatin 75 mg/m(2) + cetuximab 250 mg/m(2) (loading dose: 400 mg/m(2))
Number of subjects: 66
Study 23726971 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Platinum/5-fluorouracil plus cetuximab)
Number of subjects: 66
Study 23728047 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller medicine
Number of subjects: 0
Study 23728047 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 0
Study 23728047 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver perceived stress
Number of subjects: 0
Study 23728047 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver depression
Number of subjects: 0
Study 23728047 — intervention group
Group type: EXPERIMENTAL
Intervention: Child negative life events
Number of subjects: 0
Study 23728176 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAR1 knockdown
Number of subjects: 0
Study 23728176 — intervention group
Group type: COMPARATOR
Intervention: ADAR1
Number of subjects: 0
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: LBBB (Left Bundle Branch Block)
Number of subjects: 65975
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: Intraventricular conduction defect
Number of subjects: 65975
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: RBBB (Right Bundle Branch Block) combined with left anterior fascicular block
Number of subjects: 65975
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: QRS duration ≥ 140 ms in LBBB
Number of subjects: 65975
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: QRS nondipolar voltage (RNDPV)
Number of subjects: 65975
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: QRS/STT angle and ST J-point depression in aVL in LBBB
Number of subjects: 65975
Study 23729198 — intervention group
Group type: COMPARATOR
Intervention: RBBB
Number of subjects: 65975
Study 23729493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult ADHD Symptoms Rating Scale (ASRS)
Number of subjects: 1171
Study 23729493 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement invariance across gender and age groups
Number of subjects: 1171
Study 23729493 — intervention group
Group type: EXPERIMENTAL
Intervention: Total ASRS-ADHD score
Number of subjects: 1171
Study 23729493 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of scores between genders
Number of subjects: 1171
Study 23729989 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exposure (N = 662, 53%)
Number of subjects: 1263
Study 23729989 — intervention group
Group type: COMPARATOR
Intervention: No trauma exposure
Number of subjects: 1263
Study 23729989 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 1263
Study 23729989 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of presenting anxiety disorder
Number of subjects: 1263
Study 23730928 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating (CDR) by trained community health workers (CHWs)
Number of subjects: 90
Study 23730928 — intervention group
Group type: COMPARATOR
Intervention: Physician diagnosis
Number of subjects: 90
Study 23730928 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis
Number of subjects: 90
Study 23731330 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc plus optimized background therapy (OBT)
Number of subjects: 206
Study 23731760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) from related donors, mean of 6 × 10(5)/kg
Number of subjects: 18
Study 23731760 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (historic control)
Number of subjects: 18
Study 23731760 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs treatment
Number of subjects: 18
Study 23731760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological analysis post-MSC treatment
Number of subjects: 18
Study 23731770 — intervention group
Group type: EXPERIMENTAL
Intervention: 124I-iodoazomycin galactopyranoside (124I-IAZGP)
Number of subjects: 10
Study 23731832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months
Number of subjects: 54
Study 23731998 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) in 0.9% sodium chloride (saline)
Number of subjects: 7000
Study 23731998 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 7000
Study 23732043 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (PI and NNRTI)
Number of subjects: 82
Study 23732043 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine and efavirenz
Number of subjects: 82
Study 23732043 — intervention group
Group type: COMPARATOR
Intervention: Unboosted atazanavir
Number of subjects: 82
Study 23732043 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CD4+ count
Number of subjects: 82
Study 23732904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (4-dose schedule at 0, 1, 2, and 12 months)
Number of subjects: 0
Study 23732904 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dose of hepatitis B virus (HBV) vaccine
Number of subjects: 0
Study 23733030 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 11
Study 23733030 — intervention group
Group type: EXPERIMENTAL
Intervention: AD efficacy
Number of subjects: 11
Study 23733030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 11
Study 23733041 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Vaccines)
Number of subjects: 0
Study 23733198 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEi)
Number of subjects: 1163
Study 23733198 — intervention group
Group type: COMPARATOR
Intervention: Non-ACE inhibitors
Number of subjects: 1163
Study 23733473 — intervention group
Group type: EXPERIMENTAL
Intervention: PaMZ (PA-824-moxifloxacin-pyrazinamide) given at human-equivalent doses 5 days/week for 8 weeks
Number of subjects: 0
Study 23733473 — intervention group
Group type: COMPARATOR
Intervention: RHZ (rifampin-isoniazid-pyrazinamide) given 5 days/week for 8 weeks
Number of subjects: 0
Study 23733473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both combination regimens (PaMZ and RHZ)
Number of subjects: 0
Study 23733802 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 2
Study 23733802 — intervention group
Group type: COMPARATOR
Intervention: No mTOR inhibitor treatment (Control)
Number of subjects: 2
Study 23733925 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1427
Number of subjects: 0
Study 23733925 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1404
Number of subjects: 0
Study 23733925 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1428
Number of subjects: 0
Study 23733925 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1405
Number of subjects: 0
Study 23733925 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-labeled PSMA inhibitors
Number of subjects: 0
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 200 μg
Number of subjects: 96
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 400 μg
Number of subjects: 96
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 800 μg
Number of subjects: 96
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (VI) 12.5 μg
Number of subjects: 96
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 96
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate and Vilanterol (FF/VI) 800/50 μg
Number of subjects: 96
Study 23735179 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (VI) 50 μg
Number of subjects: 96
Study 23735475 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve replacement using the Melody valve
Number of subjects: 311
Study 23735475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics treatment for all patients diagnosed with IE
Number of subjects: 311
Study 23735475 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV-related infective endocarditis
Number of subjects: 311
Study 23735475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical outcomes
Number of subjects: 311
Study 23735702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) at a dose of 40 mg/m² every 28 days for six courses
Number of subjects: 60
Study 23735728 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative monocyte counts
Number of subjects: 115
Study 23735728 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative C-reactive protein (CRP) levels
Number of subjects: 115
Study 23736357 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental policies supporting physical activity (PA)
Number of subjects: 0
Study 23736357 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting access to unhealthy foods
Number of subjects: 0
Study 23736357 — intervention group
Group type: EXPERIMENTAL
Intervention: Role modeling of healthy eating behaviors
Number of subjects: 0
Study 23736357 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting access to unhealthy foods and role modeling
Number of subjects: 0